US 12,268,662 B2
Formulations comprising carbachol and brimonidine to enhance anti- presbyopia effects
Rhett Schiffman, Seattle, WA (US); and Bruce Firestone, Seattle, WA (US)
Assigned to VISUS THERAPEUTICS, INC., Seattle, WA (US)
Filed by VISUS THERAPEUTICS, INC., Seattle, WA (US)
Filed on Dec. 6, 2023, as Appl. No. 18/531,082.
Application 18/531,082 is a continuation of application No. PCT/US2022/079625, filed on Nov. 10, 2022.
Claims priority of provisional application 63/278,081, filed on Nov. 10, 2021.
Prior Publication US 2024/0100009 A1, Mar. 28, 2024
Int. Cl. A61K 31/498 (2006.01); A61K 9/00 (2006.01); A61K 31/27 (2006.01); A61K 47/38 (2006.01); A61P 27/10 (2006.01)
CPC A61K 31/27 (2013.01) [A61K 9/0048 (2013.01); A61K 31/498 (2013.01); A61K 47/38 (2013.01); A61P 27/10 (2018.01)] 11 Claims
 
1. An ophthalmic formulation comprising 2.75 wt % carbachol, or a pharmaceutically acceptable salt thereof, 0.1 wt % brimonidine, or a pharmaceutically acceptable salt thereof, 0.2 wt % hydroxypropylmethyl cellulose (HPMC), and a phosphate buffer, wherein the ophthalmic formulation does not contain a preservative.